 |
Intranasal Therapeutics, Inc. (ITI) is a private company founded in 1998 by Edwin Cohen, founder and former Chairman and CEO of Barr Laboratories, Inc. |
Welcome to ITI
Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative nasally delivered pharmaceutical products, with a particular focus on drugs treating pain and disorders related to the central nervous system for which there is proven, unsatisfied consumer need. Our market-driven strategy is designed to capitalize on our unique expertise and proprietary technology to develop an array of promising new drug therapies, from product concept to commercialization. MORE
Latest News
- April 4, 2007- ITI Appoints Pharmaceutical Industry Veteran, Peter F. Young, as President and Chief Executive Officer MORE
- December 6, 2006 - ITI Adds Key Executives to Management Team. MORE
- August 15, 2006 - ITI Closes $39.1 Million Series A Venture Financing. MORE
Promising products, major milestones
 |
We have two lead products in our clinical pipeline and several other in formulation or in preclinical phase. Our second patent has been issued, and our sterile filling and manufacturing facility has been completed. MORE |
Comfort.
Convenience.
Control.
Nasal drug delivery products have many benefits over alternative therapies, with the potential to enhance the health and well-being of those who use them. MORE
Contact Us
For more information about nasal drug delivery contact us at info@intranasal.com
